Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Ovarian Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
46 drugs · 161 active trials
11 drugs · 195 active trials
5 drugs · 126 active trials
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Carboplatin | Approved | Phase 4 | 52 | 26 | 61 | 282 | 2 | US | Aug 8, 2025 | 1989-04 |
| Cyclophosphamide | Approved | Phase 3 | 24 | 10 | 4 | 84 | 1 | US | Sep 12, 2023 | 1991-02 |
| Gemcitabine | Approved | Phase 3 | 20 | 9 | 21 | 89 | 3 | US | Aug 4, 2011 | 1998-01 |
| Doxorubicin | Approved | Phase 3 | 18 | 10 | 17 | 68 | 1 | US | Nov 17, 1995 | 1991-04 |
| Topotecan | Approved | Phase 3 | 12 | 6 | 29 | 86 | 2 | EU, US | May 28, 1996 | 1992-10 |
| Bevacizumab | Phase 4 | Phase 4 | 68 | 40 | 37 | 164 | 0 | — | — | 2002-04 |
| Paclitaxel | Phase 4 | Phase 4 | 65 | 31 | 80 | 306 | 0 | — | — | 1994-01 |
| Olaparib | Phase 4 | Phase 4 | 35 | 13 | 17 | 80 | 0 | — | — | Jul 8, 2008 |
| Niraparib | Phase 4 | Phase 4 | 13 | 9 | 8 | 46 | 0 | — | — | Jun 21, 2013 |
| Palbociclib | Phase 4 | Phase 4 | 8 | 5 | 0 | 13 | 0 | — | — | Aug 17, 2015 |
| Pegfilgrastim | Phase 4 | Phase 4 | 2 | 2 | 1 | 12 | 0 | — | — | 2002-06 |
| Lenvatinib | Phase 4 | Phase 4 | 2 | 0 | 0 | 7 | 0 | — | — | 2010-03 |
| Dexamethasone | Phase 4 | Phase 4 | 1 | 1 | 2 | 8 | 0 | — | — | 1998-05 |
| Sunitinib | Phase 4 | Phase 4 | 1 | 0 | 0 | 8 | 0 | — | — | 2007-01 |
| Pazopanib | Phase 4 | Phase 4 | 0 | 0 | 1 | 14 | 0 | — | — | 2006-03 |
| Aspirin | Phase 4 | Phase 4 | 0 | 0 | 0 | 3 | 0 | — | — | May 4, 2018 |
| Pembrolizumab | Phase 3 | Phase 3 | 38 | 15 | 3 | 85 | 0 | — | — | Aug 26, 2010 |
| Cisplatin | Phase 3 | Phase 3 | 17 | 9 | 19 | 81 | 0 | — | — | 1991-04 |
| Nivolumab | Phase 3 | Phase 3 | 13 | 1 | 1 | 29 | 0 | — | — | Nov 15, 2013 |
| Chemotherapy | Phase 3 | Phase 3 | 11 | 7 | 11 | 35 | 0 | — | — | 1996-03 |
| Oxaliplatin | Phase 3 | Phase 3 | 7 | 4 | 1 | 21 | 0 | — | — | 1999-09 |
| Letrozole | Phase 3 | Phase 3 | 7 | 5 | 5 | 17 | 0 | — | — | 2003-09 |
| Durvalumab | Phase 3 | Phase 3 | 5 | 2 | 1 | 18 | 0 | — | — | Dec 19, 2013 |
| Cediranib | Phase 3 | Phase 3 | 5 | 0 | 4 | 16 | 0 | — | — | 2005-10 |
| Atezolizumab | Phase 3 | Phase 3 | 5 | 2 | 4 | 15 | 0 | — | — | Mar 8, 2017 |
| Mirvetuximab Soravtansine | Phase 3 | Phase 3 | 5 | 4 | 5 | 13 | 0 | — | — | Mar 2, 2016 |
| Etoposide | Phase 3 | Phase 3 | 4 | 3 | 6 | 32 | 0 | — | — | 1989-04 |
| Talazoparib | Phase 3 | Phase 3 | 4 | 2 | 1 | 13 | 0 | — | — | Jan 3, 2011 |
| Trastuzumab | Phase 3 | Phase 3 | 4 | 1 | 1 | 9 | 0 | — | — | 2001-11 |
| Docetaxel | Phase 3 | Phase 3 | 3 | 0 | 4 | 43 | 0 | — | — | 1995-07 |
| Carboplatin/Paclitaxel Regimen | Phase 3 | Phase 3 | 3 | 0 | 5 | 10 | 0 | — | — | 2003-04 |
| Bleomycin | Phase 3 | Phase 3 | 3 | 3 | 5 | 7 | 0 | — | — | 1989-04 |
| Hyperthermic Intraperitoneal Chemotherapy | Phase 3 | Phase 3 | 3 | 0 | 2 | 5 | 0 | — | — | 2012-01 |
| Veliparib | Phase 3 | Phase 3 | 2 | 0 | 1 | 19 | 0 | — | — | 2007-08 |
| Nab-paclitaxel | Phase 3 | Phase 3 | 2 | 2 | 1 | 14 | 0 | — | — | 2006-05 |
| Rucaparib | Phase 3 | Phase 3 | 2 | 0 | 5 | 14 | 0 | — | — | 2007-12 |
| Capecitabine | Phase 3 | Phase 3 | 2 | 1 | 1 | 12 | 0 | — | — | 1998-12 |
| Adjuvant Chemotherapy | Phase 3 | Phase 3 | 2 | 1 | 3 | 5 | 0 | — | — | Jul 20, 2012 |
| Anastrozole | Phase 3 | Phase 3 | 2 | 2 | 1 | 4 | 0 | — | — | 2003-10 |
| Filgrastim | Phase 3 | Phase 3 | 1 | 1 | 3 | 42 | 0 | — | — | 1991-10 |
| Pemetrexed | Phase 3 | Phase 3 | 1 | 0 | 1 | 13 | 0 | — | — | 2004-07 |
| Tamoxifen | Phase 3 | Phase 3 | 1 | 0 | 3 | 10 | 0 | — | — | 1996-09 |
| Avelumab | Phase 3 | Phase 3 | 1 | 0 | 3 | 8 | 0 | — | — | Dec 21, 2015 |
| Trabectedin | Phase 3 | Phase 3 | 1 | 1 | 3 | 7 | 0 | — | — | 2005-04 |
| Pertuzumab | Phase 3 | Phase 3 | 1 | 0 | 1 | 6 | 0 | — | — | 2003-05 |
| Dostarlimab | Phase 3 | Phase 3 | 1 | 0 | 2 | 5 | 0 | — | — | 2019-12 |
| Alpelisib | Phase 3 | Phase 3 | 1 | 1 | 1 | 3 | 0 | — | — | Jul 22, 2021 |
| Axitinib | Phase 3 | Phase 3 | 1 | 0 | 1 | 2 | 0 | — | — | Sep 29, 2021 |
| Lurbinectedin | Phase 3 | Phase 3 | 1 | 1 | 1 | 2 | 0 | — | — | 2015-05 |
| Trametinib | Phase 3 | Phase 3 | 1 | 0 | 1 | 2 | 0 | — | — | Apr 11, 2014 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.